ChemicalBook >> CAS DataBase List >>INDEX NAME NOT YET ASSIGNED

INDEX NAME NOT YET ASSIGNED

CAS No.
2487550-41-2
Chemical Name:
INDEX NAME NOT YET ASSIGNED
Synonyms
PD-1/PD-L1-IN-10;(2-((3-Cyanobenzyl)oxy)-4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-5-nitrobenzyl)-L-threonine;Lewis,T-lymphocyte,tumor,IFN-γ,Inhibitor,lung,LLC,inhibit,Apoptosis,PD1/PDL1IN10,PD 1/PD L1 IN 10,carcinoma,PD-1/PD-L-1-IN-10
CBNumber:
CB69322433
Molecular Formula:
C33H31N3O7
Molecular Weight:
581.63
MDL Number:
MFCD34474011
MOL File:
2487550-41-2.mol
Last updated:2024-07-02 08:55:14

INDEX NAME NOT YET ASSIGNED Properties

Boiling point 824.5±65.0 °C(Predicted)
Density 1.35±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO : 100 mg/mL (171.93 mM; Need ultrasonic)
pka 2.03±0.13(Predicted)
form Solid
color White to off-white

INDEX NAME NOT YET ASSIGNED Chemical Properties,Uses,Production

Biological Activity

PD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy[1]. PD-1/PD-L1-IN-10 (compound B2) significantly promotes interferongamma secretion in a dose-dependent manner in vitro even at the low concentration of 1 nM[1].PD-1/PD-L1-IN-10 (compound B2) does not affect cell viability of LLC cells and lymph node T-cells[1].PD-1/PD-L1-IN-10 (compound B2, 0-100 nM) stabilizes the PD-L1 protein in mouse Lewis lung carcinoma (LLC) cells. In particular, PD-1/PD-L1-IN-10 (compound B2) maintains the PD-L1 stability in a dose-dependent manner at 58 °C. Suggesting that PD-1/PD-L1-IN-10 (compound B2) could enter LLC cells and then directly binds to the PD-L1 protein[1]. PD-1/PD-L1-IN-10 (compound B2, 5 mg/kg, intragastric gavage) exhibits potent in vivo anticancer efficacy in an LLC-bearing allograft mouse model. PD-1/PD-L1-IN-10 (compound B2) effectively blocks tumor cell proliferation and induces apoptosis in LLC tumor tissues.[1].

References

[1]. Yiqiang OuYang, et al. Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo. J Med Chem. 2021 May 26.

INDEX NAME NOT YET ASSIGNED Preparation Products And Raw materials

Raw materials

Preparation Products

INDEX NAME NOT YET ASSIGNED Suppliers

Global( 6)Suppliers
Supplier Tel Email Country ProdList Advantage
TargetMol Chemicals Inc.
+1-781-999-5354 support@targetmol.com United States 19973 58
Shanghai Beckham Medical Technology Co., Ltd 021-13816613772 13816613772 huahero21@sina.com China 408 55
Jinan Jiuli Biotechnology Co. , Ltd. 15865264761 486064515@qq.com China 3223 58
Bide Pharmatech Ltd. 400-1647117 13681763483 product02@bidepharm.com China 62163 58
Shanghai Yifei Biotechnology Co. , Ltd. 021-65675885 18964387627 customer_service@efebio.com China 11976 58
RD International Technology Co., Limited 18024082417 market@ubiochem.com China 9268 58

INDEX NAME NOT YET ASSIGNED Spectrum

PD-1/PD-L1-IN-10 Lewis,T-lymphocyte,tumor,IFN-γ,Inhibitor,lung,LLC,inhibit,Apoptosis,PD1/PDL1IN10,PD 1/PD L1 IN 10,carcinoma,PD-1/PD-L-1-IN-10 (2-((3-Cyanobenzyl)oxy)-4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-5-nitrobenzyl)-L-threonine 2487550-41-2